Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of polish population

Polish Journal of Pharmacology

Volumn 54, Issue 5, 2002, Pages 495-500

  Jamroziak, Krzysztof ^a   Balcerczak, Ewa ^a   Młynarski, Wojciech ^a   Mirowski, Marek ^a   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

C3435T polymorphism; MDR1; P glycoprotein; Pharmaco genetics

Indexed keywords

ANTHRACYCLINE; CALCIUM CHANNEL BLOCKING AGENT; CARRIER PROTEIN; CEFAZOLIN; CEFOTETAN; CYCLOSPORIN A; DIGOXIN; DILTIAZEM; GENE PRODUCT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; RITONAVIR; TAXANE DERIVATIVE; VERAPAMIL; VINCA ALKALOID;

ADULT; ALLELE; ARTICLE; CANCER THERAPY; CAUCASIAN; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG TRANSPORT; DRUG UPTAKE; EUROPE; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAPAN; MALE; POLAND; POLYMERASE CHAIN REACTION; RACE DIFFERENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL ANALYSIS; TREATMENT PLANNING; ADOLESCENT; GENETICS; GENOTYPE; POPULATION GENETICS;

ADOLESCENT; ADULT; ALLELES; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; GENOTYPE; HUMANS; MALE; P-GLYCOPROTEIN; POLAND; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0036400925     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ambdukar S.V, Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M.: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 361-398.
2. Ameyaw M.M., Regateiro F., Li T., Liu X., Tariq M., Mobarek A., Thornton N., Folayan G.O., Githang'a J., Indalo A., Ofori-Adjei D., Price-Evans D.A., McLeod H.L.: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics, 2001, 11, 217-221.
3. Brinkmann U., Roots I., Eichelbaum M.: Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov. Today, 2001, 6, 835-839.
4. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., Schaeffeler E., Eichelbaum M., Brinkmann U., Roots I.: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther., 2001, 69, 169-174.
5. Decleves X., Chevillard S., Charpentier C., Vielh P., Laplanche J.L.: A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encoding the P-glycoprotein. Hum. Mutat., 2000, 15, 486.
6. Fellay J., Marzolini C., Meaden E.R., Back D.J., Buclin T., Chave J.P., Decosterd L.A., Furrer H., Opravil M., Pantaleo G., Retelska D., Ruiz L., Schinkel A.H., Vernazza P., Eap C.B., Telenti A.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet, 2002, 359, 30-36.
7. Hitzl M., Drescher S., van der Kuip H., Schaffeler E., Fischer J., Schwab M., Eichelbaum M., Fromm M.F.: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics, 2001, 11, 293-298.
8. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Brinkmann U.: Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Nat. Acad. Sci. USA, 2000, 97, 3473-3478.
9. Ito S., Ieiri I., Tanabe M., Suzuki A., Higuchi S., Otsubo K.: Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT in healthy Japanese subjects. Pharmacogenetics, 2001, 11, 175-184.
10. Jamroziak K., Balcerczak E., Młynarski W., Mistygacz M., Mirowski M., Trelińska J., Robak T.: Occurrence of C3435T polymorphism of MDR1 (multidrug resistance-1) gene encoding P-glycoprotein in children with acute lymphoblastic leukemie (Polish). Acta Haematol. Pol., 2002, 33, Suppl. 1, 174.
11. Juliano R.L., Ling V.: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 1976, 455, 152-162.
12. Kawasaki E.S.: Sample preparation from blood, cells, and other fluids. In: PCR Protocols: A Guide to Methods and Applications. Eds. Innis M.A., Gelfand D.H., Sninsky J.J., White T.J. Academic Press, Inc., San Diego, 1990, 146-152.
13. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V, Schwarz U.I., Taylor A., Xie H.G., McKinsey J., Zhou S., Lan L.B., Schuetz J.D., Schuetz E.G., Wilkinson G.R.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther., 2001, 70, 189-199.
14. Leith C., Kopecky J., Chen I.M., Eijdems L., Slovak L.M., McConnell T.S., Head D.R., Appelbaum F.R., Willman C.L.: Frequency and clinical significance of the expression of the multidrug resistance protein MDR1/P-glycoprotein, MRP1 and LRP in acute myeloid leukemia. A South-West Oncology Group (SWOG) study. Blood, 1999, 94, 1086-1099.
15. Linder M.W., Prough R.A., Valdes R.: Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem., 1997, 43, 254-266.
16. Nauck M., Stein U., von Karger S., Marz W., Wieland H.: Rapid detection of the C3435T polymorphism of Multidrug Resistance Gene-1 using fluorogenic hybrydization probes. Clin. Chem., 2000, 46, 1995-1997.
17. Sakaeda T., Nakamura T., Horinouchi M., Kakumoto M., Ohmoto N., Sakai T., Morita Y., Tamura T., Aoyama N., Hirai M., Kasuga M., Okumura K.: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharmacol. Res., 2001, 18, 1400-1404.
18. Schaeffeler E., Eichelbaum M., Brinkmann U., Penger A., Asante-Poku S., Zanger U.M., Schwab M.: Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet, 2001, 358, 383-384.
19. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A., Borst P.: Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest., 1995, 96, 1698-1705.
20. Stanulla M., Schaeffeler E., Schrappe M., Rathmann A., Arens S., Welte K., Eichelbaum M., Zanger U., Schwab M.: An association between the MDR1 C3435T polymorphism and CNS relapse in childhood acute lymphoblastic leukemia. Blood, 2001, 98, 317a.
21. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y, Takahashi M., Kurata Y, Kigawa J., Higuchi S., Terakawa N., Otsubo K.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther., 2001, 297, 1137-1143.
22. von Ahsen N., Richter M., Grupp C., Ringe B., Oellerich M., Armstrong V.W.: No influence of MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V Allele) on dose-adjusted cyclosporine A through concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem., 2001, 47, 1048-1052.